FrancophonIA/ELRC3.0 huggingface dataset:
English: Likewise, Evista is indicated for the treatment of osteoporosis or established osteoporosis in women with BMD of the spine 2.5 SD below the mean value of a normal young population and/or with vertebral fractures, irrespective of BMD.
Danish: Ligeledes er Evista indiceret til behandling af osteoporose eller etableret osteoporose hos kvinder med BMD af rygsøjlen på 2,5 SD under middelværdien for en normal ung population og/eller med vertebrale frakturer, uanset BMD.
English: Evista has no effect on the risk of ER negative breast cancers.
Danish: Evista har ingen indvirkning på risikoen for østrogenreceptor-negativ brystcancer.
English: In the osteoporosis treatment study, significantly fewer Evista-treated patients required initiation of hypolipidaemic therapy compared to placebo.
Danish: I osteoporosebehandlingsundersøgelsen havde signifikant færre Evista-behandlede patienter behov for påbegyndelse af lipidsænkende behandling i forhold til placebo.
English: Raloxifene modestly increases hormone-binding globulin concentrations, including sex steroid binding globulins (SHBG), thyroxine binding globulin (TBG), and corticosteroid binding globulin (CBG), with corresponding increases in total hormone concentrations.
Danish: Raloxifen øger i beskedent omfang koncentrationerne af hormonbindende globulin, inklusiv kønshormonbindende globuliner (SHBG), thyroxinbindende globulin (TBG) og kortikosteroidbindende globulin (CBG) med tilsvarende stigninger i totale hormonkoncentrationer.
English: In clinical trials, Evista did not stimulate the postmenopausal uterine endometrium.
Danish: I kliniske studier stimulerede Evista ikke det postmenopausale endometrium.
English: Due to the nature of this disease process, Evista is intended for long term use.
Danish: Evista er beregnet til langvarig brug på grund af karakteren af sygdomsprocessen.
English: • If you are suffering from breast cancer, as there is insufficient experience of Evista use in women with this disease.
Danish: • hvis De har brystkræft, idet der er begrænset erfaring med brug af Evista hos kvinder med denne sygdom.
English: What you need to know before you take Evista
Danish: Det skal De vide, før De begynder at tage Evista
English: Evista does not stimulate breast tissue.
Danish: Evista stimulerer ikke brystvæv.
English: Based on these risk factors, prevention of osteoporosis with Evista is indicated for women within ten years of menopause, with BMD of the spine between 1.0 and 2.5 SD below the mean value of a normal young population, taking into account their high lifetime risk for osteoporotic fractures.
Danish: Baseret på disse risikofaktorer er osteoporoseforebyggelse med Evista indiceret hos kvinder inden for ti år efter menopausen med BMD af rygsøjlen mellem 1,0 og 2,5 SD under middelværdien for en normal ung population, under hensyntagen til deres høje livstidsrisiko for osteoporotiske frakturer.
English: When determining the choice of Evista or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5.1).
Danish: Når valget mellem Evista eller anden behandling, inklusiv østrogener, skal tages for den enkelte postmenopausale kvinde, bør menopausale symptomer, effekt på uterint væv og brystvæv og kardiovaskulære risici og fordele indgå i overvejelserne (se pkt.
English: Evista is only for use in postmenopausal women.
Danish: Evista må kun anvendes af postmenopausale kvinder.
English: • Decrease in the number of the platelets in the blood
Danish: • Færre blodplader i blodet
English: There was no difference between Evista and placebo treated women in the incidences of vaginal bleeding (spotting) or vaginal discharge.
Danish: Der var ingen forskel mellem Evista- og placebo-behandlede kvinder i forekomsten af vaginal blødning (pletblødning) eller vaginalt udflåd.
English: Evista mimics some of the helpful effects of oestrogen after the menopause.
Danish: Evista efterligner nogle af de gavnlige virkninger af østrogen efter overgangsalderen.
English: Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Danish: Yderligere oplysninger om Evista findes på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu.
English: Evista (n = 317) was compared with continuous combined (n = 110) hormone replacement therapy (HRT) or cyclic (n = 205) HRT patients in some clinical trials.
Danish: Evista (n = 317) blev i visse kliniske lægemiddelstudier sammenlignet med hormonal substitutionsterapi, som blev givet som kontinuerlig (n = 110) eller cyklisk (n = 205) kombinationsbehandling.
English: Evista is indicated for the treatment and prevention of osteoporosis in postmenopausal women.
Danish: Evista er indiceret til behandling og forebyggelse af osteoporose hos postmenopausale kvinder.
English: In postmenopausal women with osteoporosis, Evista reduces the incidence of vertebral fractures, preserves bone mass and increases bone mineral density (BMD).
Danish: Hos postmenopausale kvinder med osteoporose reducerer Evista forekomsten af vertebrale frakturer, bevarer knoglemassen og øger knoglemineraltætheden (BMD).
English: Across all placebo-controlled trials, Evista was indistinguishable from placebo with regard to frequency and severity of breast symptoms (no swelling, tenderness and breast pain).
Danish: I alle placebokontrollerede studier var der ingen forskel mellem Evista og placebo med hensyn til frekvens og sværhedsgrad af brystsymptomer (ingen hævelse, ømhed og brystsmerter).
English: Serum total bilirubin, gamma-glutamyl transferase, alkaline phosphatase, ALT and AST should be closely monitored during treatment if elevated values are observed.
Danish: Hvis der observeres forhøjede værdier af total-serumbilirubin, gamma-glutamyltransferase, alkalisk fosfatase, ALAT og ASAT, bør disse parametre overvåges nøje under behandlingen.
English: Tell your doctor or pharmacist.
Danish: Kontakt lægen eller apoteket.
English: During an average follow-up of 5.6 years, 59 (1.2%) raloxifene-treated women died due to a stroke compared to 39 (0.8%) placebo-treated women.
Danish: I løbet af en gennemsnitlig opfølgningstid på 5,6 år døde 59 (1,2%) raloxifenbehandlede kvinder af et apopleksi sammenlignet med 39 (0,8%) placebo-behandlede kvinder.
English: Marketing Authorisation Holder Daiichi Sankyo Europe GmbH, Zielstattstrasse 48, D-81379 Munich, Germany.
Danish: Indehaveren af markedsføringstilladelsen Daiichi Sankyo Europe GmbH, D-81379 München, Tyskland.
English: Reproductive system and breast disorders Common: Mild breast symptoms a such as pain, enlargement and tenderness General disorders and administration site conditions Very common: Flu syndrome
Danish: Det reproduktive system og mammae Almindelig: Lette symptomer i brysteta såsom smerter, hævelse og ømhed Almene symptomer og reaktioner på administrationsstedet Meget almindelig: Influenzalignende syndrom Almindelig: Perifert ødem
English: Flu syndrome was reported by 16.2 % of Evista treated patients and 14.0 % of placebo treated patients.
Danish: Influenzalignende syndrom blev rapporteret af 16,2 % af de patienter, som blev behandlet med Evista, og af 14,0 % af de patienter, som blev behandlet med placebo.
English: Other medicines and Evista
Danish: Brug af anden medicin sammen med Evista
English: A relative risk of 1.60 (CI 0.95, 2.71) was observed in Evista treated patients compared to placebo.
Danish: En relativ risiko på 1,60 (konfidensinterval 0,95-2,71) blev observeret hos Evista-behandlede patienter i forhold til placebo.
English: In a study comparing Evista with oestrogen, bone from patients treated with either medicinal product was histologically normal, with no evidence of mineralisation defects, woven bone or marrow fibrosis.
Danish: I en sammenlignende undersøgelse med Evista overfor østrogen var patienternes knoglevæv under begge behandlinger histologisk normalt uden tegn på mineraliseringsdefekter, ikke-lamellær knogle (woven bone) eller knoglemarvsfibrose.
English: BATCH NUMBER Lot {number}
Danish: BATCHNUMMER Lot:
English: 84 film coated tablets
Danish: 84 filmovertrukne tabletter
English: Evista contains lactose
Danish: Evista indeholder lactose
English: MARKETING AUTHORISATION NUMBER(S) EU/1/98/073/001 14 film coated tablets EU/1/98/073/002 28 film coated tablets EU/1/98/073/003 84 film coated tablets
Danish: EU/1/98/073/001 14 filmovertrukne tabletter EU/1/98/073/002 28 filmovertrukne tabletter EU/1/98/073/003 84 filmovertrukne tabletter
English: NAME OF THE MARKETING AUTHORISATION HOLDER Daiichi Sankyo Europe GmbH
Danish: NAVN PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN Daiichi Sankyo Europe GmbH
English: Evista reduced the incidence of clinical vertebral fractures by 35% compared with placebo (HR 0.65, CI 0.47
Danish: Evista nedsatte forekomsten af kliniske vertebrale frakturer med 35% sammenlignet med placebo (HR 0,65, konfidensinterval 0,47 - 0,89).
English: Anhydrous lactose Lactose monohydrate Crospovidone Magnesium stearate
Danish: Vandfri lactose Lactosemonohydrat Crospovidon Magnesiumstearat
English: In the 4th year alone, Evista reduced the new vertebral fracture risk by 39 % (RR 0.61, CI 0.43, 0.88).
Danish: I det fjerde år alene reducerede Evista risikoen for nye vertebrale frakturer med 39% (relativ risiko 0,61, konfidensinterval 0,43-0,88).
English: Evista contains lactose.
Danish: Evista indeholder lactose.
English: • If there is still a possibility that you can get pregnant, Evista could harm your unborn child.
Danish: • hvis De stadigvæk har mulighed for at blive gravid.
English: Driving and using machines Evista has no or negligible effects on driving or using machines.
Danish: Trafik- og arbejdssikkerhed Evista påvirker ikke eller kun i ubetydelig grad evnen til at køre bil eller betjene maskiner.
English: Compared with placebo-treated patients the occurrence of vasodilatation (hot flushes) was modestly increased in Evista patients (clinical trials for the prevention of osteoporosis, 2 to 8 years postmenopausal, 24.3 % Evista and 18.2 % placebo; clinical trials for the treatment of osteoporosis, mean age 66, 10.6 % for Evista and 7.1 % placebo).
Danish: Sammenlignet med placebobehandlede patienter var forekomsten af vasodilatation (hedestigninger) let øget hos patienter, som blev behandlet med Evista (kliniske studie til forebyggelse af osteoporose, 2 til 8 år postmenopausal, 24,3 % for Evista og 18,2 % for placebo; kliniske studier til behandling af osteoporose, gennemsnitlig alder på 66 år, 10,6 % for Evista og 7,1 % for placebo).
English: • This medicine has been prescribed for you only.
Danish: • Lægen har ordineret Evista til Dem personligt.
English: PHARMACEUTICAL FORM Film coated tablet.
Danish: LÆGEMIDDELFORM Filmovertrukne tabletter.
English: This leaflet was last revised in month YYYY.
Danish: Denne indlægsseddel blev senest ændret: måned ÅÅÅÅ
English: Evista contains the active substance raloxifene hydrochloride.
Danish: Evista indeholder det aktive indholdsstof raloxifenhydrochlorid.
English: • Medicinal product subject to medical prescription
Danish: • Lægemidlet er receptpligtigt.
English: Evista should not be used in patients with severe renal impairment (see section 4.3).
Danish: Evista bør ikke anvendes til patienter med svært nedsat nyrefunktion (se pkt.
English: Evista produced significant increases in bone density of hip and spine as well as total body mineral mass compared to placebo.
Danish: Evista øgede knoglemineraltætheden i hofte og rygsøjle samt knoglemassen i hele kroppen signifikant i forhold til placebo.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 60 mg raloxifene hydrochloride, equivalent to 56 mg raloxifene free base.
Danish: KVALITATIV OG KVANTITATIV SAMMENSÆTNING Hver filmovertrukken tablet indeholder 60 mg raloxifenhydrochlorid svarende til 56 mg raloxifen fri base.
English: In a study of 7,705 postmenopausal women with a mean age of 66 years and with osteoporosis or osteoporosis with an existing fracture, Evista treatment for 3 years reduced the incidence of vertebral fractures by 47 % (RR 0.53, CI 0.35, 0.79; p < 0.001) and 31 % (RR 0.69, CI 0.56, 0.86; p < 0.001) respectively.
Danish: I en undersøgelse af 7.705 postmenopausale kvinder med en gennemsnitlig alder på 66 år og med osteoporose eller osteoporose med en eksisterende fraktur, reducerede 3 års behandling med Evista forekomsten af vertebrale frakturer med henholdsvis 47 % (relativ risiko 0,53, konfidensinterval 0,35-0,79; p < 0,001) og 31 % (relativ risiko 0,69, konfidensinterval 0,56-0,86; p < 0,001).
English: NAME OF THE MEDICINAL PRODUCT Evista 60 mg film coated tablets
Danish: LÆGEMIDLETS NAVN Evista 60 mg filmovertrukne tabletter
English: Another adverse reaction observed was leg cramps (5.5 % for Evista, 1.9 % for placebo in the prevention population and 9.2 % for Evista, 6.0 % for placebo in the treatment population).
Danish: En anden observeret bivirkning var kramper i benene (5,5 % for Evista og 1,9 % for placebo blandt deltagere i studier til forebyggelse af osteoporose og 9,2 % for Evista og 6,0 % for placebo blandt deltagere i studie til behandling af osteoporose).
English: PHARMACEUTICAL FORM AND CONTENTS 14 film coated tablets
Danish: LÆGEMIDDELFORM OG INDHOLD (PAKNINGSSTØRRELSE) 14 filmovertrukne tabletter
English: PHARMACEUTICAL FORM AND CONTENTS 100 film coated tablets
Danish: LÆGEMIDDELFORM OG INDHOLD (PAKNINGSSTØRRELSE) 100 filmovertrukne tabletter
English: Evista 60 mg film coated tablets raloxifene hydrochloride
Danish: Evista 60 mg filmovertrukne tabletter raloxifenhydrochlorid
English: Evista lowers total cholesterol and LDL ("bad") cholesterol.
Danish: Evista sænker det samlede kolesterol og LDL (”farligt”) kolesterol.
English: 28 film coated tablets
Danish: 28 filmovertrukne tabletter
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 5 August 1998
Danish: DATO FOR FØRSTE MARKEDSFØRINGSTILLADELSE/FORNYELSE AF TILLADELSEN
English: Therefore Evista is not recommended to be used in patients with hepatic insufficiency.
Danish: Derfor kan Evista ikke anbefales til patienter med nedsat leverfunktion.
English: Evista treatment for 4 years reduced the incidence of vertebral fractures by 46 % (RR 0.54, CI 0.38, 0.75) and 32 % (RR 0.68, CI 0.56, 0.83) in patients with osteoporosis or osteoporosis with an existing fracture respectively.
Danish: Behandling med Evista i 4 år reducerede forekomsten af vertebrale frakturer med 46% (relativ risiko 0,54, konfidensinterval 0,38-0,75) og 32% (relativ risiko 0,68, konfidensinterval 0,56-0,83) hos patienter med henholdsvis osteoporose eller osteoporose med en eksisterende fraktur.
English: In patients with moderate and mild renal impairment, Evista should be used with caution.
Danish: Evista bør anvendes med forsigtighed til patienter med let til moderat nedsat nyrefunktion.
English: In the prevention population discontinuations of therapy due to any adverse reaction occurred in 10.7 % of 581 Evista treated patients and 11.1 % of 584 placebo-treated patients.
Danish: Blandt deltagere i studier til forebyggelse af osteoporose forekom behandlingsophør som følge af enhver bivirkning hos 10,7 % af 581 Evista-behandlede patienter og hos 11,1 % af 584 placebobehandlede patienter.
English: Store in the original package.
Danish: Opbevares i originalemballagen.
English: In the treatment population discontinuations of therapy due to any clinical adverse event occurred in 12.8 % of 2,557 Evista treated patients and 11.1 % of 2,576 placebo treated patients.
Danish: Blandt deltagere i studier til behandling af osteoporose forekom behandlingsophør som følge af enhver bivirkning hos 12,8 % af 2.557 Evista-behandlede patienter og hos 11,1 % af 2.576 placebo-behandlede patienter.
English: Lilly SA
Danish: Lilly S.A.
English: Over the 4 years of the osteoporosis treatment trial (involving 7,705 patients), Evista treatment compared to placebo reduced the risk of total breast cancer by 62 % (RR 0.38; CI 0.21, 0.69), the risk of invasive breast cancer by 71 % (RR 0.29, CI 0.13, 0.58) and the risk of invasive oestrogen receptor (ER) positive breast cancer by 79 % (RR 0.21, CI 0.07, 0.50).
Danish: I løbet af de 4 års osteoporosebehandlings studier (med 7705 patienter), reducerede Evista-behandling risikoen for brystcancer i forhold til placebo med 62% (relativ risiko 0,38, konfidensinterval 0,210,69), risikoen for invasiv brystcancer med 71% (relativ risiko 0,29, konfidensinterval 0,13-0,58) samt risikoen for invasiv østrogenreceptor-positiv brystcancer med 79% (relativ risiko 0,21, konfidensinterval 0,07-0,50).
English: Evista reduces the risk of vertebral fractures in women with postmenopausal osteoporosis.
Danish: Evista nedsætter risikoen for brud på rygsøjlen hos kvinder med knogleskørhed efter overgangsalderen.
English: Uncommon: Fatal strokes
Danish: Ikke almindelig: Apopleksi med dødelig udgang
English: What Evista contains - The active substance is raloxifene hydrochloride.
Danish: Evista indeholder: - Aktivt stof: raloxifenhydrochlorid.
English: Fewer Evista treated women than placebo treated women required surgical intervention for uterine prolapse.
Danish: Færre Evista-behandlede kvinder havde behov for et operativt indgreb for uterint prolaps end placebo-behandlede kvinder.
English: NAME OF THE MEDICINAL PRODUCT EVISTA 60 mg film coated tablets raloxifene hydrochloride
Danish: LÆGEMIDLETS NAVN EVISTA 60 mg filmovertrukne tabletter raloxifenhydrochlorid
English: Common: Headache, including migraine a
Danish: Nervesystemet Almindelig: Hovedpine herunder migrænea
English: You should check with your doctor or pharmacist if you are not sure.
Danish: Spørg lægen eller på apotekspersonalet, hvis der er noget, De er i tvivl om.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each film coated tablet contains 60 mg raloxifene hydrochloride, equivalent to 56 mg raloxifene
Danish: ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver filmovertrukken tablet indeholder 60 mg raloxifenhydrochlorid svarende til 56 mg raloxifen
English: Evista does not treat postmenopausal symptoms, such as hot flushes.
Danish: Evista kan ikke lindre symptomer, såsom hedestigninger, som opstår i forbindelse med overgangsalderen.
English: There is no relevant use of Evista in the paediatric population.
Danish: Evista bør ikke anvendes til børn uanset alder. Der er ingen relevante indikationer for Evista i den pædiatriske population.
English: Uncommon: Thrombocytopenia a
Danish: Ikke almindelig: Trombocytopenia
English: Musculoskeletal and connective tissue disorders Common: Leg cramps
Danish: Knogler, led, muskler og bindevæv Almindelig: Kramper i benene
English: The clinically most important adverse reactions reported in postmenopausal women treated with Evista were venous thromboembolic events (see section 4.4), which occurred in less than 1% of treated patients.
Danish: De vigtigste, kliniske bivirkning, som er rapporteret hos postmenopausale kvinder behandlet med Evista, var venøse tromboemboliske hændelser (se pkt.
English: NN:
Danish: Tryk:
English: Evista must not be taken by women of child bearing potential.
Danish: Evista må ikke anvendes af fertile kvinder.
English: SN:
Danish: EXP:
English: This was peripheral oedema, which occurred in the prevention population at an incidence of 3.1 % for Evista and 1.9 % for placebo; and in the treatment population occurred at an incidence of 7.1 % for Evista and 6.1 % for placebo.
Danish: Perifert ødem, som ikke var statistisk signifikant (p > 0,05), men som viste en signifikant dosistendens, forekom med en hyppighed på 3,1 % for Evista og 1,9 % for placebo blandt deltagere i studier til forebyggelse af osteoporose og med en hyppighed på 7,1 % for Evista og 6,1 % for placebo blandt deltagere i studie til behandling af osteoporose.
English: Very common: Gastrointestinal symptoms a such as nausea, vomiting, abdominal pain, dyspepsia Skin and subcutaneous tissue disorders
Danish: Mave-tarm-kanalen Meget almindelig: Gastrointestinale symptomera som kvalme, opkastning, abdominalsmerter,
English: Evista is used to treat and prevent osteoporosis in postmenopausal women.
Danish: Evista bruges til at behandle og forebygge knogleskørhed hos kvinder, der har passeret overgangsalderen (postmenopausal osteoporose).
English: What Evista looks like and contents of the pack Evista are white, oval, film coated tablets which are marked with the number 4165.
Danish: Evista er hvide, ovale tabletter med et filmovertræk.
English: EXPIRY DATE EXP {MM/YYYY}
Danish: UDLØBSDATO Udløbsdato: {MM/ÅÅÅÅ}
English: What Evista is and what it is used for What you need to know before you take Evista How to take Evista
Danish: Det skal De vide, før De begynder at tage Evista Sådan skal De tage Evista Bivirkninger
English: Ink:
Danish: Lot:
English: Common: Peripheral oedema
Danish: Almindelig: Hududslæta
English: If you take more Evista than you should you could have leg cramps and dizziness.
Danish: De kan få kramper i benene eller blive svimmel, hvis De har taget flere Evista tabletter, end De skal.
English: How to take Evista
Danish: Sådan skal De tage Evista
English: Uncommon: Venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, retinal vein thrombosis, superficial vein thrombophlebitis, Arterial thromboembolic reactions a
Danish: tromboflebitis i overfladiske vener, arterielle tromboemboliske bivirkningera
English: in the lungs (pulmonary embolism) or in the eyes (retinal vein thrombosis).
Danish: lungeemboli, retinal venetrombose,
English: Nervous system disorders
Danish: Nedsat nyrefunktion
English: Keep this medicine out of the sight and reach of children.
Danish: Opbevar lægemidletutilgængeligt for børn.
English: Evista should not be used in children of any age.
Danish: Opbevares utilgængeligt for børn.
English: NE=median was not reached.
Danish: NE = median blev ikke nået.
English: The median age was 51 years and 13% were 65 years or older.
Danish: Median alder var 51 år, og 13 % var 65 år eller ældre.
English: Don't take any more tablets.
Danish: Tag ikke flere tabletter.
English: • Risk management Plan (RMP)
Danish: • Risikostyringsplan (RMP)
English: This effect decreases with increasing age from approximately 40 to 60 years.
Danish: Denne effekt faldt med stigende alder fra ca. 40 år til 60 år.
English: * Post hoc analysis
Danish: *Post hoc-analyse.
English: Symptoms may include:
Danish: Symptomerne kan inkludere:
English: Date of first authorisation: 10 June 2008 Date of latest renewal: 17 February 2015
Danish: Dato for første markedsføringstilladelse: 10. juni 2008 Dato for seneste fornyelse: 17. februar 2015
English: The primary endpoint was time to progression (TTP).
Danish: Det primære endepunkt var tid til progression (TTP).
English: The clinical relevance of this effect has not been evaluated.
Danish: Den kliniske relevans af denne virkning er ikke blevet evalueret.
English: You are responsible to decide if you are able to drive a motor vehicle or perform other tasks that require increased concentration.
Danish: Det er dit ansvar at beslutte, om du er i stand til at køre eller udføre andre opgaver, der kræver øget koncentration.
English: If possible, show them the pack.
Danish: Vis pakningen, hvis det er muligt.
English: Overall 58 % of these symptomatic patients recovered.
Danish: I alt 58 % af disse symptomatiske patienter kom sig.
English: Component of a multipack, cannot to be sold separately.
Danish: Del af en multipakning, kan ikke sælges separat.
English: The daily dose of Tyverb should not be divided.
Danish: Den daglige dosis af Tyverb bør ikke deles.
English: The frequency of some side effects is not known (it cannot be estimated from the available data):
Danish: Hyppigheden af nogle bivirkninger kendes ikke (kan ikke fastsættes ud fra tilgængelige data):
English: • avoid milk and milk products (including ice cream)
Danish: • undgå mælk og mælkeprodukter (herunder is)
English: In addition, 150 [50%] of patients were hormone receptor negative.
Danish: Derudover var 150 [50 %] af patienterne hormonreceptornegative.
English: These medicines include some medicines in the following groups:
Danish: Dette gælder for noget medicin i de følgende grupper: